Regional Clinical and Biochemical Differences among Patients with Primary Hyperparathyroidism

This study had been presented at the 6th ESES Biennial Scientific Meeting held in Cardiff (15-17 May 2014).Address for Correspondence: Dr. Özer Makay, Department of General Surgery, Division of Endocrine Surgery, Ege University School of Medicine, İzmir, TurkeyPhone: +90 232 390 50 50 Received: 13 July 2015 e-mail: ozer.makay@ege.edu.trAccepted: 27 January 2016 o DOI: Background: Environmental habitat may play a role in clinical disparities of primary hyperparathyroidism (pHPT) patients. Aims: To compare preoperative clinical symptoms and associated conditions and surgical findings in patients with pHPT, living in different geographical regions from the Black Sea, Mediterranean and Anatolia regions. Study Design: Retrospective, clinical-based multicentric study of 694 patients with pHPT.Methods: Patients from 23 centers and 8 different geographical regions were included. Data related to baseline demographics, clinical, pathologic and treatment characteristics of 8 regions were collected and included age, gender, residential data, symptoms, history of fracture, existence of brown tumor, serum total Ca and p levels, serum parathormone (PTH) levels, serum 25-OH vitamin D levels, bone mineral density, size of the resected abnormal parathyroid gland(s), histology, adenoma, and multiple endocrine neoplasia (MEN)- or familial-related disease.Results: The median age was 54. Asymptomatic patient rate was 25%. The median PTH level was 232 pg/mL and serum total Ca was 11.4 mg/dL. Eighty-seven percent of patients had an adenoma and 90% of these had a single adenoma. Hyperplasia was detected in 79 patients and cancer in 9 patients. The median adenoma size was 16 mm. Significant parameters differing between regions were preoperative symptoms, serum Ca and p levels, and adenoma size. All patients from South-East Anatolia were symptomatic, while the lowest p values were reported from East Anatolia and the largest adenoma size, as well as highest Ca levels, were from Bulgaria.Conclusion: Habitat conditions vary between geographical regions. This affects the clinicopathological features of patients with pHPT.

PDF

___

1. Kirdak T, Duh QY, Kebebew E, Clark OH. Do patients undergoing parathyroidectomy for primary hyperparathyroidism in San Francisco, CA, and Bursa, Turkey, differ? Am J Surg 2009;198:188-92.
2. O'Neal P, Mowschenson P, Connolly J, Hasselgren PO. Large parathyroid tumors have an increased risk of atypia and carcinoma. Am J Surg 2011;202:146-50.
3. Bae JH, Choi HJ, Lee Y, Moon MK, Park YJ, Shin CS, et al. Preoperative predictive factors for parathyroid carcinoma in patients with primary hyperparathyroidism. J Korean Med Sci 2012;27:890-5
4. Chang YJ, Mittal V, Remine S, Manyam H, Sabir M, Richardson T, et al. Correlation between clinical and histological findings in parathyroid tumors suspicious for carcinoma. Am Surg 2006;72;419-26.
5. Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002;17 Suppl 2:N18-23.
6. Abood A, Vestergaard P. Increasing incidence of primary hyperparathyroidism in Denmark. Dan Med J 2013;60:A4567.
7. Bachir BG, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, et al.
Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system. Can Urol Assoc J 2013;E667-72.
8. Kadry Z, Schaefer EW, Uemura T, Shah AR, Schreibman I, Riley TR 3rd. Impact of geographic disparity on liver allocation for hepatocellular cancer in the United States. J Hepatol 2012;56:618-25.
9. Ehieli EI, Karamlou T, Diggs BS, Walker WL, Caddell KA, de la Cruz JS, et al. Regional variation in prosthesis choice for aortic valve replacement in older patients. J Heart Valve Dis 2012;21:12-9.
10. De Lucia F, Minisola S, Romagnoli E, Pepe J, Cipriani C, Scillitani A, et al. Effect of gender and geographic location on the expression of primary hyperparathyroidism. J Endocrinol Invest 2013;36:123-6.
11. Chapter IV. Chemistry of sea water (1982-2004) In: The Oceans Their Physics, Chemistry, and General Biology. P:168 Available from: http:// publishing.cdlib.org/ucpressebooks/view?docId=kt167nb66r&chunk. id=ch06&toc.id=ch06&brand=eschol. Accessed 03 January, 2014.
12. Oguz T, Violette PE, Unluata U. The upper layer circulation of the Black Sea: its variability as inferred from hydrographic and satellite observation. J Geophys Res 1992;12:569-84.
13. Spencer DW, Brewer PG, Sachs PL. Aspects of the distribution and trace element composition of suspended matter in the Black Sea. Geochim Cosmochim Acta 1972;36:71-86.
14. Norman J, Goodman A, Politz D. Calcium, parathyroid hormone, and vitamin D in patients with primary hyperparathyroidism: normograms developed from 10,000 cases. Endocr Pract 201;17:384-94.
15. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:171-7.
16. Randhawa PS, Mace AD, Nouraei SA, Stearns MP. Primary hyperparathyroidism: do perioperative biochemical variables correlate with parathyroid adenoma weight or volume? Clin Otolaryngol 2007;32:179- 84.
17. Cavallaro G, Cucina A, Coluccia P, Petramala L, Cotesta D, Polistena A, et al. Role of growth factors on human parathyroid adenoma cell proliferation. World J Surg 2010;34:48-54.
18. Wang IJ. Examining the full effects of landscape heterogeneity on spatial genetic variation: a multiple matrix regression approach for quantifying geographic and ecological isolation. Evolution 2013;67:3403-11.
19. Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2000;85:1054-8.
20. Atli T, Gullu S, Uysal AR, Erdogan G. The prevalence of Vitamin D deficiency and effects of ultraviolet light on Vitamin D levels in elderly Turkish population. Arch Gerontol Geriatr 2005;40:53-60.
21. van Schoor NM, Lips P. Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab 2011;25:671-80.
22. Tassone F, Gianotti L, Baffoni C, Visconti G, Pellegrino M, Cassibba S, et al. Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clin Endocrinol (Oxf) 2013;79:784-90.
23. Rao RR, Randeva HS, Sankaranarayanan S, Narashima M, Möhlig M, Mehanna H, et al. Prolonged treatment with vitamin D in postmenopausal women with primary hyperparathyroidism. Endocr Connect 2012;1:13-21.
24. Untch BR, Barfield ME, Dar M, Dixit D, Leight GS Jr, Olson JA Jr. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 2007;142:1022-6.
25. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005;63:506-13.
26. Yamashita H, Noguchi S, Uchino S, Watanabe S, Koike E, Murakami T, et al. Vitamin D status in Japanese patients with hyperparathyroidism: seasonal changes and effect on clinical presentation. World J Surg 2002;26:937-41.
27. Saliba W, Lavi I, Rennert HS, Rennert G. The evaluation of vitamin D status in normocalcemic primary hyperparathyroidism. Eur J Inter Med 2013;24:e8.
28. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 2006;29:511-5.
29. Perez-Lopez FR, Brincat M, Erel CT, Tremollieres F, Gambacciani M, Lambrinoudaki I. EMAS position statement: Vitamin D and postmenopausal health. Maturitas 2012;71:83-8.